Immunovant, Inc. (IMVT) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST
Conference Call Participants
Stephanie Lee Griffin – Roivant Sciences Ltd.
Matthew Gline – Roivant Sciences Ltd.
David Risinger – Leerink Partners LLC, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Yaron Werber – TD Cowen, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Yuchen Ding – Jefferies LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Hao Shen – Wells Fargo Securities, LLC, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Brandon Frith – Wolfe Research, LLC
Gaurav Maini – LifeSci Capital, LLC, Research Division
Presentation
Operator
Thank you for standing by. Welcome to the Roivant Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today’s conference is being recorded.
I will now hand the conference over to your first speaker, Stephanie Lee. You may begin.
Stephanie Lee Griffin
Roivant Sciences Ltd.
Good morning, and thanks for joining today’s call to review Roivant’s financial results for the second quarter ended September 30, 2025. I’m Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We’ll also be providing the current slide numbers as we present to help you follow along.
I’d like to remind you that we will be making certain forward-looking statements during today’s presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties.
And with that, I’ll turn it over to Matt.
